Systemic Radiotherapy of Bone Metastases With Radionuclides Academic Article

abstract

• Treatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and samarium-153 ethylenediaminetetramethylene phophanate (EDTMP) for the palliation of pain from bone metastases, as well as the evidence for the use of radium-223 in metastatic castrate-resistant prostate cancer. Efforts to optimise treatments and improve response rates, either by safely increasing the radiation dose to bone metastases or by combining treatment with non-radiation-based therapies, are discussed. In addition, the development of both alpha- and beta-particle-emitting radiopharmaceuticals designed to target prostate-specific membrane antigen are reviewed.

authors

• Murray, I
• Du, Yong

status

• published 

publication date

• February 2021

has subject area

• 1112 Oncology and Carcinogenesis (FoR)
• Bone Neoplasms (MeSH)
• Humans (MeSH)
• Male (MeSH)
• Oncology & Carcinogenesis (Science Metrix)
• Palliative Care (MeSH)
• Prostatic Neoplasms (MeSH)
• Radioisotopes (MeSH)
• Radiopharmaceuticals (MeSH)
• Veterinary Sciences (Science Metrix)

published in

• Clinical Oncology Comparative Haematology International  Journal

keywords

• Bone Neoplasms
• Humans
• Male
• Palliative Care
• Prostatic Neoplasms
• Radioisotopes
• Radiopharmaceuticals

Digital Object Identifier (DOI)

• 10.1016/j.clon.2020.11.028

PubMed ID

• 33353771

start page

• 98

end page

• 105

volume

• 33

issue

• 2